Clinical Trials Sponsored by Accuray Incorporated

Total 1197 results

Encore Medical, L.P.
DJO Incorporated

Completed

Encore Revelation Hip Stem

Osteoarthritis, Hip | Complications; Arthroplasty

United States
Vertex Pharmaceuticals Incorporated
ViroChem Pharma

Completed

A Proof-of-concept Study of VCH-759 for the Treatment of Hepatitis C-infection.

Hepatitis C, Chronic

Canada
Angitia Incorporated Limited

Recruiting

A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers

Osteogenesis Imperfecta

United States
University of Georgia
Cotton Incorporated

Recruiting

Cottonseed Oil Dose Response

Dyslipidemias | Overweight and Obesity | Nutrition, Healthy

United States
Vertex Pharmaceuticals Incorporated
CRISPR Therapeutics

Recruiting

Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

Hematologic Diseases | Genetic Diseases, Inborn | Sickle Cell Disease | Hemoglobinopathies | Sickle Cell Anemia | Thalassemia | Beta-Thalassemia

United States, Italy, Germany, Saudi Arabia
Vertex Pharmaceuticals Incorporated
CRISPR Therapeutics

Recruiting

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)

Hematologic Diseases | Genetic Diseases, Inborn | Hemoglobinopathies | Thalassemia | Beta-Thalassemia

United States, Germany, Italy, United Kingdom, Canada
Insmed Incorporated
Muscular Dystrophy Association

Completed

Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1

Myotonic Dystrophy Type 1

United States
Parion Sciences
Vertex Pharmaceuticals Incorporated

Completed

Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia (CLEAN-PCD)

Primary Ciliary Dyskinesia

United States, United Kingdom, Netherlands, Denmark, Canada, Italy, Germany, Poland
Toyos Clinic
Bausch & Lomb Incorporated

Completed

Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%

Inflammation | Pseudophakia
Bausch & Lomb Incorporated
ORA, Inc.

Completed

Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants

Hyperemia

United States
GlycoMimetics Incorporated
University of Michigan

Completed

Phase I Study to Assess Safety and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects

Healthy Volunteers

United States
Ingredion Incorporated
KGK Science Inc.

Completed

Post-prandial Glycemic Response to Fiber in Healthy Adults

Glucose, Low Blood | Glucose, High Blood | Meals
Vertex Pharmaceuticals Incorporated
Janssen Pharmaceuticals

Terminated

An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus

Hepatitis C

United States, United Kingdom, Spain, Belgium, Italy, Germany
Vertex Pharmaceuticals Incorporated
ViroChem Pharma

Completed

Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection

Hepatitis C

Canada, United States, Argentina, Puerto Rico
Hvidovre University Hospital
DJO Incorporated

Completed

Non-operative Treatment of Acute Achilles Tendon Rupture Using Dynamic Rehabilitation. Influence of Early Weight-bearing Compared With Non-weight-bearing

Acute Achilles Tendon Rupture

Denmark
Tibotec BVBA
Vertex Pharmaceuticals Incorporated

Completed

VX-950HEP1001 - Drug-drug Interaction Study Between Telaprevir and Raltegravir

Hepatitis C
University of Toronto
Ingredion Incorporated

Completed

Types of Starch and Their Effect on Blood Glucose, Appetite and Food Intake

Diabetes Prevention | Obesity Prevention

Canada
University of Toronto
Ingredion Incorporated

Completed

Types of Starch and Their Effect on Blood Glucose, Appetite and Food Intake

Diabetes Prevention | Obesity Prevention

Canada
University of Rochester
Bausch & Lomb Incorporated

Completed

Objective Evaluation of Ocular Surface Lubricants in Two Environments

Dry Eye

United States
University of Arizona
Cook Group Incorporated

Completed

Multi-center:The Small (14F) Percutaneous Catheter vs. Large (28-40F) Open Chest Tube for Traumatic Hemothorax (P-CAT) (P-CAT)

Traumatic Hemothorax | The Efficacy of Percutaneous Catheter vs. Open Chest Tube

United States
Johns Hopkins University
Erbe USA Incorporated

Completed

Endoscopic Gastric Mucosal Devitalization (GMD) as a Primary Obesity Therapy (GMD)

Obesity | Obesity, Morbid | Bariatric Surgery Candidate | Obesity; Endocrine

United States
Ohio State University
Bausch & Lomb Incorporated

Completed

Accommodative Relief for Uncomfortable Non-Presbyopes

Asthenopia

United States
University of Florida
Vertex Pharmaceuticals Incorporated

Completed

Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1 (STEADFAST)

Hepatitis C, Chronic

United States
Lifelong Vision Foundation
Bausch & Lomb Incorporated

Completed

A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis

Keratoconjunctivitis Due to Adenovirus | Viral Shedding

United States
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation (KONTINUE)

Cystic Fibrosis

United States, France, Belgium, United Kingdom
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation

Cystic Fibrosis

United States, United Kingdom, Canada
OrthoCarolina Research Institute, Inc.
DJO Incorporated

Terminated

Motorized Continuous Cold Therapy Versus Standard Post-op Icing Protocol for Two Foot and Ankle Procedures

Pain | Patient Satisfaction | Wound Healing | Narcotic Consumption

United States
University of Pittsburgh
Gen-Probe, Incorporated

Completed

Non-Invasive Sexually Transmitted Disease Testing in Women Seeking Emergency Contraception or Urine Pregnancy Testing

Trichomonas Vaginitis | Chlamydia Trachomatis | Neisseria Gonorrhoeae Infection

United States
University of Rochester
Bausch & Lomb Incorporated

Completed

Non-invasive Tear Film Dynamic Measurements in Normal, MGD and ADDE Subjects After Saline Instillation

Aqueous Deficient Dry Eye | Meibomium Gland Dysfunction

United States
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation (KONNECTION)

Cystic Fibrosis

United States, France, Belgium
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)

Hepatitis C

Australia, Canada, France, Italy, Poland, United Kingdom, Germany, United States, Spain, Israel, Argentina, Puerto Rico, Austria
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

Virology Follow up Study in Subjects Previously Treated With Telaprevir

Hepatitis C

United States, France, Canada, Germany, Puerto Rico
Genta Incorporated
National Cancer Institute (NCI)

Unknown

Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer

Lung Cancer

United States, Canada, Russian Federation
Genta Incorporated

Completed

Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Leukemia

United States
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation (STRIVE)

Cystic Fibrosis

United States, Canada, Australia, Ireland, France, United Kingdom, Germany, Czech Republic
Proacta, Incorporated
National Cancer Institute (NCI)

Completed

PR-104 in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Safety Study of Ivacaftor in Subjects With Cystic Fibrosis

Cystic Fibrosis

United States, Canada, Germany
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation (ENVISION)

Cystic Fibrosis

United States, Australia, Canada, France, Germany, Ireland, United Kingdom
Johns Hopkins University
Erbe USA Incorporated

Completed

Safety of a Sheath Cryoprobe Bronchoscopic Transbronchial Biopsy Technique (FROSTBITE)

Lung Diseases

United States
University of Michigan
Vironix Health Incorporated

Withdrawn

Emergency Department (ED) Self-Monitoring Pilot COVID-19

Covid-19 | SARS-CoV 2 | COVID
University of Waterloo
Bausch & Lomb Incorporated

Completed

Changes in the Tear Film With Scleral Contact Lens Wear for Keratoconic Eyes

Keratoconus
Alios Biopharma Inc.
Vertex Pharmaceuticals Incorporated

Completed

A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

Chronic Hepatitis C

Moldova, Republic of
Alios Biopharma Inc.
Vertex Pharmaceuticals Incorporated

Terminated

First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1

Hepatitis C, Chronic

Australia, New Zealand
University of Iowa
Bausch & Lomb Incorporated

Completed

Evaluation of the Bausch & Lomb PureVision Under Nighttime Driving Conditions

Astigmatism

United States
Family Works Incorporated
Oregon Research Institute

Completed

Online Parent Training for Children With Behavior Disorders (PW2)

Parenting | Delinquency

United States
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation

Cystic Fibrosis

United States, United Kingdom, Canada
University of Michigan
Bausch & Lomb Incorporated

Completed

Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol Etabonate 0.5% (Lotemax_BMT)

Dry Eyes
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Terminated

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation (DISCOVER)

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation

Cystic Fibrosis

United States

Clinical Trials Sponsored by Accuray Incorporated

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations